Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect
- 479 Downloads
A lactic acid bacterial strain was isolated from human fecal specimen and identified as Enterococcus faecalis SL-5. The isolated strain showed antimicrobial activity against Gram-positive pathogens assayed, especially the highest activity against Propionibacterium acnes. The antimicrobial substance was purified and verified as a bacteriocin (named ESL5) of E. faecalis SL-5 by activity-staining using P. acnes as an indicator. N-terminal sequence of ESL5 was determined (MGAIAKLVAK) and sequence analysis revealed that it is almost identical to the some of enterocins including L50A/B of E. faecium L50 and MR10A/B of E. faecalis MRR 10-3. From the sequencing data of L50A/B structural genes, the nucleotide sequence showed 100% identity with that of the MR10A/B structural genes, implying that ESL5 is an equivalent of enterocin MR10. Meanwhile, we also tested the therapeutic effect of anti-P. acnes activity in patients with mild to moderate acne because of its pathogenic role to acne vulgaris. For this purpose, a concentrated powder of CBT SL-5 was prepared using cell-free culture supernatant (CFCS) of E. faecalis SL-5 and included in a lotion for application in the patients. The study showed that CBT SL-5 lotion significantly reduced the inflammatory lesions like pustules compared to the placebo lotion. Therefore our results indicate that the anti-P. acnes activity produced by E. faecalis SL-5 has potential role to the treatment of acne as an alternative to topical antibiotics.
Keywordsacne vulgaris antimicrobial activity cell-free culture supernatant
Unable to display preview. Download preview PDF.
- Amenta, M., M.T. Cascio, P. Di Fiore, and I. Venturini. 2006. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11+FOS Actilight). Acta Biomed. 3, 157–162.Google Scholar
- Field, D., P. Cotter, C. Hill, and R.P. Ross. 2007. Bacteriocin biosynthesis, structure, and function, p. 5–41. In M.A. Riley and O. Gillor (eds.). Research and applications in bacteriocins, Horizon Bioscience, Wymondham, Norfolk, UK.Google Scholar
- Kim, C.H., G.E. Ji, and C. Ahn. 2000. Purification and molecular characterization of a bacteriocin from Pediococcus sp. KCA1303-10 isolated from fermented flatfish. Food Sci. Biotechnol. 9, 270–276.Google Scholar
- Kirjavainen, P.V., H.S. ElNezami, S.J. Salminen, J.T. Ahokas, and P.F. Wright. 1999. Effects of orally administered viable Lactobacillus rhamnosus GG and Propionibacterium freudenreichii subsp. shermanii JS on mouse lymphocyte proliferation. Clin. Diagn. Lab. Immunol. 6, 799–802.PubMedGoogle Scholar
- Martín-Platero, A.M., E. Valdivia, M. Ruíz-Rodriguez, J.J. Soler, M. Martín-Vivaldi, M. Maqueda, and M. Martínez-Bueno. 2006. Characterization of antimicrobial substances produced by Enterococcus faecalis MRR 10-3, isolated from the uropygial gland of the hoopoe (Upupa epops). Appl. Environ. Microbiol. 72, 4245–4249.PubMedCrossRefGoogle Scholar
- Sherman, P.M., K.C. Johnson-Henry, H.P. Yeung, P.S. Ngo, J. Goulet, and T.A. Tompkins. 2005. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect. Immun. 73, 5183–5188.PubMedCrossRefGoogle Scholar